FIELD: medicine.SUBSTANCE: group of inventions relates to a cannabinoid-based solubilisate. Solubilisate consisting of three or more than three components, namely curcumin in an amount less than or equal to 10 wt.%, at least one cannabinoid as at least one additional active substance and an emulsifier of polysorbate 80, or a mixture of polysorbate 80 and polysorbate 20, or a mixture of polysorbate 80 and at least one sucrose ester and dietary fatty acids, characterised by the fact that the content of emulsifier is at least 70 wt.%. Solubilisate consisting of two or more than two components, namely at least one cannabinoid, such as cannabidiol (CBD) and/or tetrahydrocannabinol (THC), in an amount less than or equal to 10 wt.% and an emulsifier of polysorbate 80, or a mixture of polysorbate 80 and polysorbate 20, or a mixture of polysorbate 80 and at least one sucrose ester and dietary fatty acids; characterised by the fact that the content of emulsifier is at least 70 wt.%. Oral capsule filled with the solubilisate, constituting a soft gelatin capsule or a hard gelatin capsule, or a soft gelatin-free capsule or a hard gelatin-free capsule, such as a cellulose capsule. Food product in the form of a fluid containing the solubilisate. Dietary supplement in the form of a fluid containing the solubilisate. Beverage in the form of a fluid containing the solubilisate. Cosmetic product in the form of a fluid containing the solubilisate. Method for preventing diseases including inflammation, cancer, Alzheimer&#39;s disease, Parkinson&#39;s disease, obesity, high cholesterol level, high blood sugar, diabetes, metabolic syndrome and/or autoimmune diseases, multiple sclerosis (MS); for reducing the visceral fat, for thermogenesis, reducing the cholesterol, such as LDL cholesterol, and/or blood glucose, and/or blood triglycerides, for improving the density of macular pigment (in the retina of the eye), for reducing the oxidative stress and/or reducing accumulation of fat in hepatocytes, for preventing hepatic obesity, Friedreich&#39;s hereditary ataxia, lysosomal diseases such as Tay-Sachs disease, atherosclerosis, cardiac diseases, arthritis; characterised by the fact that the solubilisate is administered to the consumer in a curcumin dose from 0.5 mg/kg body weight to 1 mg/kg body weight once a day. Method for producing the solubilisate, including the following stages: (a) providing an emulsifier of polysorbate 80, or a mixture of polysorbate 80 and polysorbate 20, or a mixture of polysorbate 80 and at least one sucrose ester and dietary fatty acids; (b) adding at least one cannabinoid; (c) adding curcumin powder; wherein stage (a) is execured at a temperature from 40°C to 62°C, and stage (b) is executed at a temperature from 82°C to 97°C, wherein stage (c) includes maintaining said temperature. Method for producing the solubilisate by mixing a curcumin solubilisate and a solubilisate of at least one cannabinoid in a quantitative ratio of individual solubilisates of 1:1. Method for producing a cannabinoid solubilisate, including the following stages: (a) providing an emulsifier of polysorbate 80, or a mixture of polysorbate 80 and polysorbate 20, or a mixture of polysorbate 80 and at least one sucrose ester and dietary fatty acids; (b) adding at least one cannabinoid; wherein stage (a) is executed at a temperature of at least 40°C to 62°C, and stage (b) is executed at a temperature from 82°C to 97°C.EFFECT: above solubilisate provides effective protection from oxidation of the cannabinoid, as well as from precipitation of curcumin due to the micellar structure of curcumin and cannabinoid, stable water-soluble formulation is provided, wherein the solubilisate freely dissolves in water, resulting in a turbidity-free solution.62 cl, 3 ex